The headlines on Monster Beverage are all about health concerns as at least one state’s attorney general investigates its products. But there may be something even bigger: Monster’s growth may be showing signs of peaking.
The first rule of insider trading: Don’t talk about insider trading—or do a lot of Internet searches about it.
The marketplace for narcotics isn’t what it used to be. Read ahead to see a list of dangerous drugs that are legal in many American states.
CNBC's Jackie DeAngelis and Jane Wells report on the agriculture department's response to widespread drought conditions, Merck's new osteoporosis drug, and the buyer of Edvard Munch's "The Scream."
Find out which second-quarter top performer got the most votes.
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
Peter Madoff, the younger brother of Ponzi swindler Bernie Madoff, was arrested this morning and will appear in court later in the day as part of a process that will see him serve 10 years in prison for his role in the swindle.
Jack Lief, Arena Pharmaceuticals CEO, discusses what the drug-maker's new anti-obesity drug will mean for its bottom-line, with CNBC's Seema Mody.
Newly released documents reveal that Pfizer presented a study falsely claiming that its arthritis drug, Celebrex, was safer on the stomach than competing drugs, the New York Times reports.
U.S. regulators, retailers and manufacturers are growing increasingly concerned that a surge in the number of products being recalled is resulting in "fatigue" by the public — increasing the chance that consumers could ignore or miss a recall that could ultimately endanger their health, USA Today reports.
Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.
If Americans ever eat genetically engineered fast-growing salmon, it might be because of a Soviet biologist turned oligarch turned government minister turned fish farming entrepreneur, the New York Times reports.
CNBC's Seema Mody reports on the latest details of the FDA advisory panel's review of Arena Pharmaceuticals' anti-obesity drug.
Ten days after the FDA sent warning letters to manufacturers of supplements with DMAA in it, the nation’s largest supplement retailers still have the product on the shelves.
In a wake of a warning letter sent to them by the FDA, some companies whose pre-workout or weight loss products include the ingredient DMAA, are starting to move on with life without it.
A warning letter written by the Food & Drug Administration last week to ten companies that produce pre-workout supplements with the ingredient dimethylamyamine (DMAA) has sent shockwaves through the industry, not only to the producers of the products but to consumers who have taken them.
CNBC's Darren Rovell reports on how shares of GNC Holdings and Vitamin Shoppe are holding up since Amazon.com announced they will be pulling products containing DMAA.
CNBC's Darren Rovell reports Amazon.com is pulling all products containing DMAA, an ingredient the FDA stated does not derive from a plant.
John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.
U.S. securities regulators on Wednesday finalized long-awaited rules that will dictate which companies dealing in derivatives will be subject to costly capital, margin and business conduct requirements.